Day: December 15, 2025

PHILADELPHIA, PA, Dec. 15, 2025 (GLOBE NEWSWIRE) — Crane Harbor Acquisition Corp. II (NASDAQ:CRANU) (the “Company”) today announced the upsized pricing of its initial public offering of 30,000,000 units at a price of $10.00 per unit. The Company’s units will be listed on the Nasdaq Global Market under the symbol “CRANU” and will begin trading on December 16, 2025. Each unit issued in the offering consists of one Class A ordinary share of the Company and one right to receive one fifteenth (1/15) of a Class A ordinary share upon the consummation of the Company’s initial business combination. Once the securities comprising the units begin separate trading, the Class A ordinary shares and rights are expected to be listed on NASDAQ under the symbols “CRAN” and “CRANR,” respectively. The closing of the offering is anticipated...

LITTLETON, Colo., Dec. 15, 2025 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic procedures and proprietary treatments for sleep related breathing disorders, including obstructive sleep apnea (OSA), today announced that the Company’s CEO Kirk Huntsman and CFO Brad Amman will participate in a fireside chat with Robert Sassoon, senior research analyst of Water Tower Research (“WTR”) on Tuesday, December 16, 2025, at 11:00 am ET. Vivos management will discuss the strategic business model pivot and operational execution; the market opportunity and competitive environment; and Vivos’ growth and financial strategies. To register for this listen-only event, please visit: Fireside Chat The...

FIXYR Initial Activation Processed Over 20,000 Digital Tickets and 200+ Customer Inquiries with 100% Uptime, 100% Satisfaction, and Zero Human Intervention Vancouver, BC, Dec. 15, 2025 (GLOBE NEWSWIRE) — Fobi AI Inc. (TSXV:FOBI, Pink:FOBIF) (“Fobi” or the “Company”) is pleased to announce the launch of FIXYR, the Company’s new Agentic AI Customer Service & Technical Support Platform. FIXYR is built on Fobi’s proprietary enterprise large language model infrastructure, using commercially licensed AI models deployed on secure, Canadian-hosted servers. Unlike AI solutions that build on top of third-party platforms like ChatGPT, FIXYR is designed for enterprise and regulated environments, with full data sovereignty, no external data exposure, and no dependency on third-party platforms. The platform is purpose-built to automate...

Fiscal Q2 2026 (which began on Aug 1, 2025 and ended Oct 31, 2025) included a $500M private placement, fueling BNC’s digital assets treasury transformation. World’s Largest BNB Treasury with over 500,000 BNB held, providing unmatched exposure to a leading digital asset ecosystem.LOUISVILLE, CO, Dec. 15, 2025 (GLOBE NEWSWIRE) — CEA Industries Inc. (NASDAQ: BNC), (“BNC” or the “Company”), today reported financial results for its second fiscal quarter ended October 31, 2025. “This quarter marked the definitive transformation into our new identity as BNC,” said David Namdar, CEO of CEA Industries. “By closing a $500 million financing round, launching our new ticker, and rapidly accumulating over 500,000 BNB tokens, we have successfully laid the foundation for our DAT strategy. With a strengthened Board of Directors, a launched...

Holders will have until December 30, 2025 to exercise Tranche A Warrants at $1.05 per share, enabling up to $17.9 million in potential gross proceeds BURLINGTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) — Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pioneering pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (“T2D”), today announced that it will call all of its outstanding Tranche A Common Stock Purchase Warrants (the “Tranche A Warrants”) to purchase shares of the Company’s common stock, par value $0.00001 per share (the “Common Stock”) for cancellation for cash consideration of $0.00001 per underlying share at 6:30 p.m., New York City time, on December 30, 2025 (the “Cancellation Date”). The Tranche A Warrants were issued in connection...

Arbitration Ruling Reaffirms Allogene’s Full Control of Cemacabtagene Ansegedleucel (Cema-Cel) Decision Reconfirms Allogene’s Expanded Sub-License Covering EU and UK Rights with Options for Japan and China, Clearing the Path for Allogene to Acquire Full Global Rights 1H 2026 Interim Futility Analysis from the Pivotal Phase 2 ALPHA3 Trial with Cema-Cel in First-Line (1L) Consolidation Large B-Cell Lymphoma (LBCL) Remains on TrackSOUTH SAN FRANCISCO, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today noted the favorable outcome for Servier in its arbitration with Cellectis (Euronext Growth: ALCLS –  NASDAQ: CLLS) as it relates to cemacabtagene ansegedleucel...

Phoenix, AZ, Dec. 15, 2025 (GLOBE NEWSWIRE) — InnSuites Hospitality Trust (NYSE American: IHT) reported Hotel Revenue results surpassing $5.8 million once again in the First Three Fiscal Quarters of 2026, (February 1, 2025, to October 31, 2025), with Total Revenue of approximately $5,809,673. Consolidated Net Income before the non-cash expense of depreciation and the non-cash Best Western Rewards Guest Vouchers expense, was approximately break-even at (-48,000), for the 2026 First Fiscal Three Quarters ended October 31, 2025 (February 1, 2025, through October 31, 2025). IHT hotel operations were strong in the 2025 Fiscal Year ended January 31, 2025, and are contributing to a comparable 2026 Fiscal Year. Combined Hotel November Revenue for both hotels was the second highest combined November amount of approximately $550,000, which...